Aducanumab is one of several IV monoclonal antibody infusions that have been tested for early stage Alzheimer disease (AD); the drug missed its endpoints improving the condition, and was declared dead by the company, using futility analysis. Biogen, the company, then surprisingly resurrected the project for re-interpretation and presentation to the FDA for approval. It … Continue reading Aducanumab for AD…..what if? Thought experiment by Dr. J. Karlawish